$CLVT

Clarivate (CLVT) Reports Q3 Revenue of $567.9M, Net Loss of $80.8M

Clarivate (CLVT) reported Q3 revenue of $567.9M, down from $623.1M year-over-year. Excluding the divested LS&H segment, revenue was $481.6M. The company posted a net loss of $80.8M, including a $62.2M non-cash LS&H goodwill impairment charge. The results reflect the company's transition toward Academia & Government and Intellectual Property businesses.

Original reporting
Published Nov 3, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Clarivate (CLVT) Reports Q3 Revenue of $567.9M, Net Loss of $80.8M — source image
Decision brief

The 30-second read

$CLVTBearishMed
01

Why it matters

The earnings miss may trigger short‑term sell‑offs, but the company’s focus on core Academia & Government and IP businesses could support a rebound if execution improves.

02

Market read

First‑time disclosure of Q3 results for Clarivate, a mid‑cap US‑listed data‑analytics firm, with clear implications for its stock price.

03

What to watch

Cash generation from remaining segments and potential cost synergies from the recent divestiture are not highlighted in the headline.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Clarivate Plc released its Q3 2026 earnings, noting a revenue decline after shedding its LS&H segment and a significant goodwill impairment.

Company-level read

Ticker impact

$CLVTBearishHigh confidence
Context

Q3 revenue fell to $567.9M and net loss widened to $80.8M, marking the first public disclosure of Clarivate's quarterly results.

Expected impact

downward pressure as investors price in weaker revenue and a large goodwill impairment.

Evidence & confidence

Revenue decline and a $62.2M goodwill charge signal deteriorating core performance, prompting sell‑side analysts to downgrade outlook.

Market effects

Intellectual‑property and academic‑services sector may see broader scrutiny as Clarivate signals slower growth.

U.S. tech‑focused investors could adjust exposure to data‑analytics firms.

Limited to investors tracking mid‑cap information‑services companies.

Counterpoint

The divestiture of LS&H could streamline operations and improve margins long‑term, offering a buying opportunity on the dip.

Key entities

  • Clarivate Plc

    Provider of analytics and insights for academia, government, and intellectual property.

Related articles

$CLVTMed

Clarivate Plc Q3 2026 Earnings Call Summary

Clarivate reported Q3 2026 earnings, highlighting 1.8% organic ACV growth and 300 basis points of adjusted EBITDA margin expansion. The company completed the Life Sciences & Healthcare divestiture, focusing on higher-quality, recurring revenue. Management expects Q4 2026 organic revenue growth to exceed 2% and targets 10-15% free cash flow growth in 2027. One-time transaction costs of $30 million were incurred, and free cash flow guidance was adjusted to $320M-$340M.

$CLVTHighAI 8/10

Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value Creation

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. 1 Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value Creation — Improved recurring organic revenue growth driven by portfolio transformation and AI-led innovation — — Updates 2026 financial outlook following the divestiture of Life Sciences & Healthcare

$CLVTMed

Why is Clarivate stock sliding today?

Clarivate (CLVT) stock fell 5.4% in pre-market trading after Q3 2026 results beat EPS estimates ($0.21 vs. $0.18) but missed revenue forecasts by 16.7% ($481.6M vs. $566.77M), down 9.2% YoY. Full-year revenue guidance ($1.96B-$1.98B) also fell short of consensus ($2.20B). The miss was exacerbated by portfolio disposals and cautious forward outlook.